209 related articles for article (PubMed ID: 27057805)
1. Future directions for checkpoint inhibition in melanoma.
Hamid O
Clin Adv Hematol Oncol; 2016 Feb; 14(2):85-6. PubMed ID: 27057805
[No Abstract] [Full Text] [Related]
2. Checkpoint Immunotherapy: Picking a Winner.
Teng MW; Khanna R; Smyth MJ
Cancer Discov; 2016 Aug; 6(8):818-20. PubMed ID: 27485001
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint inhibitors in breast cancer: hype or promise?
McArthur HL
Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806
[No Abstract] [Full Text] [Related]
4. Immune Checkpoint Therapy in Melanoma.
Callahan MK
Cancer J; 2016; 22(2):73-80. PubMed ID: 27111901
[TBL] [Abstract][Full Text] [Related]
5. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
Queirolo P; Boutros A; Tanda E; Spagnolo F; Quaglino P
Semin Cancer Biol; 2019 Dec; 59():290-297. PubMed ID: 31430555
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
Monteiro ID; Califano R; Mountzios G; de Mello RA
Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
[TBL] [Abstract][Full Text] [Related]
7. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.
Campbell MT; Siefker-Radtke AO; Gao J
Cancer J; 2016; 22(2):96-100. PubMed ID: 27111904
[TBL] [Abstract][Full Text] [Related]
8. Cancer Mutational Load: The More the Merrier for Immune Checkpoint Blockade Therapies.
EBioMedicine; 2016 Nov; 13():1-2. PubMed ID: 27916137
[No Abstract] [Full Text] [Related]
9. Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?
El Rassy E; Assi T; Kattan J
Future Oncol; 2017 Feb; 13(5):381-383. PubMed ID: 27884060
[No Abstract] [Full Text] [Related]
10. Clinical use of checkpoint inhibition in kidney cancer.
Clin Adv Hematol Oncol; 2016 Jun; 14(6):427-9. PubMed ID: 27379812
[No Abstract] [Full Text] [Related]
11. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
Carreau NA; Pavlick AC
Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Therapies in Prostate Cancer.
Goswami S; Aparicio A; Subudhi SK
Cancer J; 2016; 22(2):117-20. PubMed ID: 27111907
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
Pico de CoaƱa Y; Choudhury A; Kiessling R
Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
[TBL] [Abstract][Full Text] [Related]
14. Combination checkpoint blockade--taking melanoma immunotherapy to the next level.
Riley JL
N Engl J Med; 2013 Jul; 369(2):187-9. PubMed ID: 23724866
[No Abstract] [Full Text] [Related]
15. Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.
Helgadottir H; Kis L; Ljungman P; Larkin J; Kefford R; Ascierto PA; Hansson J; Masucci G
Ann Oncol; 2017 Jul; 28(7):1672-1673. PubMed ID: 28407116
[No Abstract] [Full Text] [Related]
16. Checkpoint Blockade for the Treatment of Advanced Melanoma.
Callahan MK; Flaherty CR; Postow MA
Cancer Treat Res; 2016; 167():231-50. PubMed ID: 26601865
[TBL] [Abstract][Full Text] [Related]
17. The science of checkpoint inhibition in kidney cancer.
Clin Adv Hematol Oncol; 2016 Apr; 14(4):214-7. PubMed ID: 27166601
[No Abstract] [Full Text] [Related]
18. The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma.
Albin N; Monard A; Lapiere J
Cancer Chemother Pharmacol; 2019 May; 83(5):1003-1005. PubMed ID: 30830289
[No Abstract] [Full Text] [Related]
19. Immune Checkpoint Inhibitors.
Haanen JB; Robert C
Prog Tumor Res; 2015; 42():55-66. PubMed ID: 26382943
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
Di Giacomo AM; Margolin K
Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]